Sanofi terminates Nurix STAT6 degrader SAR448272 program as Jefferies cuts price target to $36
Sanofi terminates Nurix STAT6 degrader SAR448272 program as Jefferies cuts price target to $36, reiterates Buy
- Sanofi’s termination of STAT6 degrader SAR448272 eliminates potential milestone payments and royalties for Nurix.
- Jefferies cut Nurix Therapeutics price target to $36 from $45 while reiterating its Buy rating.
- Nurix stated the program’s termination does not change its previously issued cash runway guidance.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.